Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

NicOx Buys Back Glaucoma Drug Rights From Pfizer

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.

You may also be interested in...



Glaucoma's Changing Of The Guard

Despite a crowded marketplace - with at least seven marketed drugs in at least three different classes -glaucoma remains a disease with a huge unmet need

NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate

Deal shows - once again - that all is not lost when Big Pharma hands back a product

NicOx finds new partner Bausch & Lomb for Phase II Glaucoma Candidate

Deal shows - once again - that all is not lost when Big Pharma hands back a product

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS069937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By